The α2-macroglobulin gene in AD

Background: Whereas several authors recently reported a positive association between the α2-macroglobulin gene (A2M) and late-onset AD (LOAD), others were unable to replicate these findings. Early-onset AD (EOAD) is defined as onset age <65 years. Virtually all patients with LOAD are >65 years of age. Objective: To evaluate the role of A2M in AD, the authors conducted a population-based study of EOAD and LOAD as well as a meta-analysis of all studies conducted to date. Methods: Patients with EOAD (n = 100) were derived from a population-based study in four northern provinces of the Netherlands and the area of metropolitan Rotterdam. Patients with LOAD (n = 344) were drawn from the Rotterdam Study, a population-based prospective study on residents aged 55 years and over of a Rotterdam suburb in the Netherlands. Two polymorphisms were studied, A2M-I/D and A2M-Ile1000Val, in relation to the APOE ε4 allele (APOE*4). Results: No genotypic or allelic association was found for either polymorphism in the population-based series of patients with LOAD. In patients with EOAD without APOE*4, a significant increase of carriers of A2M-1000Val was found. The meta-analysis of available published case–control data on these polymorphisms in white and mixed ethnic populations yielded no significant differences between cases and controls. Pooling the Asian studies conducted to date showed a significant decrease in the frequency of A2M-D among patients. Conclusions: These results suggest that A2M is not genetically associated with LOAD in white patients or mixed populations as found in the United States. In these populations A2M does not have clinical relevance. From a scientific perspective, the findings on EOAD and Asian patients require replication and further research in the A2M region.

[1]  G. Belle,et al.  Cholinergic dysfunction in diseases with Lewy bodies , 2000, Neurology.

[2]  P. Lantos,et al.  Alpha-2-macroglobulin intronic polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease , 1999, Neuroscience Letters.

[3]  R. Sulkava,et al.  Genetic association of α2‐macroglobulin with Alzheimer's disease in a Finnish elderly population , 1999, Annals of neurology.

[4]  H. Arai,et al.  Genetic association between alpha-2 macroglobulin and Japanese sporadic Alzheimer's disease , 1999, Neuroscience Letters.

[5]  E. Rogaev,et al.  Alpha-2 macroglobulin gene in early- and late-onset Alzheimer disease , 1999, Neuroscience Letters.

[6]  M. Gold,et al.  The alpha-2 macroglobulin gene is not associated with Alzheimer's disease in a case-control sample , 1999, Neuroscience Letters.

[7]  J. Chang,et al.  No association of alpha-2 macroglobulin gene five-nucleotide deletion with AD in Taiwan Chinese , 1999, Neurology.

[8]  M. Bullido,et al.  Apolipoprotein E promoter and α2-Macroglobulin polymorphisms are not genetically associated with Chinese late onset Alzheimer's disease , 1999, Neuroscience Letters.

[9]  C. Morris,et al.  Alpha2-macroglobulin polymorphisms in Alzheimer's disease and dementia with Lewy bodies. , 1999, Neuroreport.

[10]  N. Cairns,et al.  α-2 macroglobulin polymorphism and Alzheimer disease risk in the UK , 1999, Nature Genetics.

[11]  J. Haines,et al.  An α-2-macroglobulin insertion-deletion polymorphism in Alzheimer disease , 1999, Nature Genetics.

[12]  M. Owen,et al.  α-2 macroglobulin gene and Alzheimer disease , 1999, Nature Genetics.

[13]  M. Owen,et al.  No association between the alpha-2 macroglobulin I1000V polymorphism and Alzheimer's disease , 1999, Neuroscience Letters.

[14]  S L Normand,et al.  Meta-analysis: formulating, evaluating, combining, and reporting. , 1999, Statistics in medicine.

[15]  M. Albert,et al.  Genetic association of an (α2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease , 1998 .

[16]  A. Paterson,et al.  Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity. , 1998, JAMA.

[17]  M. Owen,et al.  Genetic studies on chromosome 12 in late-onset Alzheimer disease. , 1998, JAMA.

[18]  Steven M. Horvath,et al.  Alpha-2 macroglobulin is genetically associated with Alzheimer disease , 1998, Nature Genetics.

[19]  O. Khorkova,et al.  α2-macroglobulin associates with β-amyloid peptide and prevents fibril formation , 1998 .

[20]  A. Hofman,et al.  Incidence and risk of dementia. The Rotterdam Study. , 1998, American journal of epidemiology.

[21]  S. Paul,et al.  α2‐Macroglobulin Attenuates β‐Amyloid Peptide 1–40 Fibril Formation and Associated Neurotoxicity of Cultured Fetal Rat Cortical Neurons , 1998 .

[22]  G. Bu,et al.  α2‐Macroglobulin Complexes with and Mediates the Endocytosis of β‐Amyloid Peptide via Cell Surface Low‐Density Lipoprotein Receptor‐Related Protein , 1997 .

[23]  J. Haines,et al.  Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. , 1997, JAMA.

[24]  D. Selkoe,et al.  Degradation of Amyloid -Protein by a Serine Protease--Macroglobulin Complex (*) , 1996, The Journal of Biological Chemistry.

[25]  A. Hofman,et al.  The apolipoprotein E ε2 allele is associated with an increased risk of early‐onset alzheimer's disease and a reduced survival , 1995 .

[26]  Diederick E Grobbee,et al.  Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study , 1995, BMJ.

[27]  P. Marynen,et al.  A deletion polymorphism in the human alpha-2-macroglobulin (A2M) gene. , 1991, Nucleic acids research.

[28]  S. Tsuji,et al.  Mis-sense mutation Val→Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease , 1991, The Lancet.

[29]  J. Hardy,et al.  Amyloid precursor protein gene mutation in early-onset Alzheimer's disease , 1991, The Lancet.

[30]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[31]  D. Strickland,et al.  Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. , 1990, The Journal of biological chemistry.

[32]  A. Hofman,et al.  History of dementia and Parkinson's disease in 1st‐degree relatives of patients with Alzheimer's disease , 1989, Neurology.

[33]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[34]  A. Hofman,et al.  Apolipoprotein E4 allele in a population–based study of early–onset Alzheimer's disease , 1994, Nature Genetics.